Guide for Authors

INTRODUCTION
• Disclaimer
• Contact details for submission

BEFORE YOU BEGIN
• Ethics in publishing
• Conflict of interest
• Submission declaration
• Authorship
• Copyright transfer and ownership of data
• Special subject repositories
• Funding body agreements and policies
• Open access (OA)
• Language (usage and editing services)

• Informed consent and patient details
• Submission
• Style
• Brevity
• Undocumented claims (eg, "firstedness," "safe and effective")
• Trade names
• Sections/article type guidelines
• Article structure
• Title page
• Key words
• Classifications
• Abbreviations and acronyms
• Acknowledgements

• Artwork
• Illustration services
• Figure legends
• Tables
• Permissions and patient consent forms
• Procedure for review

AFTER ACCEPTANCE
• Use of the Digital Object Identifier
• Proofs
• Electronic publishing

AUTHOR INQUIRIES

Introduction


Disclaimer

Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), Publisher, or Academy. The Editor(s), Publisher, and Academy disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any products or services advertised in this publication, nor do they guarantee any claim made by the manufacturer of such products or services.

Contact details for submission

EDITOR
Brett Sloan, MD
Journal of the American Academy of Dermatology Case Reports
University of Connecticut

EDITORIAL OFFICE
Detra N. Davis
Managing Editor

Journal of the American Academy of Dermatology Case Reports

930 E. Woodfield Rd.

Schaumburg, IL 60173

Phone: 847-240-1005

Fax: 847-240-0101

E-mail: JAADCR@aad.org

Anna Krueger

Editorial Assistant

Journal of the American Academy of Dermatology Case Reports

930 E. Woodfield Rd.

Schaumburg, IL 60173

Phone: 847-240-1706

Fax: 847-330-8907

E-mail: JAADCR@aad.org

Contact for questions about manuscript preparation, submission, and review.

PUBLISHER

Elsevier Inc.

3251 Riverport Lane

Maryland Heights, MO 63043

Susan M. Kell, Senior Journal Manager

Phone: 215-239-3380

Fax: 215-239-3388

E-mail: s.kell@elsevier.com

Contact only for questions about the proof and publication time of your accepted paper.

Before You Begin

Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

Conflict of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

The Journal requires all authors to acknowledge, in the comments section of EES (http://ees.elsevier.com/jdcr), all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. The title page must also include a publishable statement disclosing any associations, current and over the past 5 years, that might pose a conflict of interest. These include but are not limited to employment, royalties, consultant arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no conflicting or competing interests are present, this should be indicated in the publishable disclosure statement. If the authors have competing or conflicting interests that cannot be disclosed in publishable statements, authors should list them in the comments section of EES (http://ees.elsevier.com/jdcr). They should also explain these interests as well as the reason for the need for confidentiality in a statement to the Editor. The Editor asks each reviewer to disclose any competing interests or conflicts of interest that might interfere with one’s objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests, if any, with the officers of the American Academy of Dermatology. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions to include published statements of retraction or removal of a manuscript from the archived journal table of contents and Medline database.

Each author must sign a conflict of interest statement and upload said forms with the manuscript. This form is available for download from the JAAD Case Reports Web site (http://www.jaadcasereports.org).

Submission declaration

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint; see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Authorship

All authors must have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

The JAAD Case Reports' authorship criteria are adapted from those of the International Committee of Medical Journal Editors and are delineated on the Authorship Statement. Each author must sign a conflict of interest form and upload said forms with the manuscript. This form is available on the JAAD Case Report's website: jaadcasereports.org.

Role of writers, "ghost writers," and other "third parties" involved in manuscript development and production

The involvement, nature of involvement, and affiliation or support of any medical writers, "ghost writers," or other individuals or companies or third parties participating in the development or writing of any papers must be noted and explained in the cover letter and in a publishable statement on the manuscript title page. (This does not include tasks such as typing or photocopying.) This statement will be published as part of the first-page footnotes. All individuals involved in the preparation and writing of each paper who meet the JAAD Case Reports's authorship criteria (see our Authorship Statement) must be listed as authors. The names, highest academic degree, and affiliations of any persons who contributed to writing the paper or analyzing the data who do not meet authorship criteria must be included in the paper's Acknowledgements along with a disclosure of any pertinent conflicts of interest. Individuals listed in the Acknowledgements because of such contributions to the work should provide written consent.

Copyright transfer and ownership of data

In accordance with the Copyright Act of 1976, which became effective January 1, 1978, the following statement signed by each author must accompany the manuscript submitted: "I, the undersigned author, transfer all copyright
ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I have reviewed and approve the submitted version of the manuscript and agree to its publication in the Journal of the American Academy of Dermatology Case Reports.” Each author must sign a copyright transfer form and upload said form(s) with the manuscript. Author(s) will be consulted, whenever possible, regarding republication of material. All authors must have access to the data presented and the authors and sponsor (if applicable) must agree to share original data with the editor if requested.

Special subject repositories

Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post certain articles, such as those funded by the National Institutes of Health, under its Public Access policy (see elsevier.com for more detail on the policy). Articles accepted for publication in an Elsevier journal from authors who have indicated that the underlying research reported in their articles was supported by an NIH grant will be sent by Elsevier to PMC for public access posting 12 months after final publication. The version of the article provided by Elsevier will include peer-review comments incorporated by the author into the article.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

Open access (OA)

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses: Creative Commons Attribution-NonCommercial-NoDervs: for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article. If you need to comply with your funding body policy you can apply for a CC-BY license after your manuscript is accepted for publication. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders. The publication fee for this journal is $400 for members of the American Academy of Dermatology and $550 for non-members, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier’s WebShop http://webshop.elsevier.com/languagingeediting/ or visit our customer support site http://support.elsevier.com for more information.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals, http://www.elsevier.com/patient-consent-policy. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.
Submit your article
Please submit your article via http://ees.elsevier.com/jdcr.

The site provides instructions for manuscript submission as well as a tutorial for authors. Word, WordPerfect, RTF, and Text files will be accepted; Word and WordPerfect are preferred. Please note that online-only materials should be provided in the same format. Questions about the program may be addressed to JAADCR@aad.org. All manuscript submissions must include the copyright transfer form, the conflict of interest disclosure form, the authorship statement (attestation) form, and the manuscript submission checklist. These forms can be downloaded from either our Web site (http://www.jaadcasereports.org) or EES (http://ees.elsevier.com/jdcr). Please scan the completed forms and upload them to EES with your submission. If this presents a problem, please contact support@elsevier.com.

Original manuscripts will be considered for publication. Correct preparation of the manuscript will expedite the review and publication procedures. Please note the following requirements.

The original page-numbered copy of the manuscript must be double-spaced. The title page should be numbered page 1. Please line number all submissions before creating the PDF. This continuous line numbering will help our reviewers with writing their comments and should speed the peer-review process. To add line numbers to your Word manuscript file, select File/Page Setup/Layout/Line Numbering/Add line numbering/Continuous, and save the changes.

Style
Manuscripts must conform to acceptable English usage. Consult the latest edition of The Chicago Manual of Style by The University of Chicago Press or the Manual of Style by the American Medical Association for current usage. Abbreviations must be limited primarily to those in general usage. Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.

Brevity
Brevity is appreciated.

Undocumented claims (eg, "firstedness," "safe and effective")

Please do not claim that your report is the first reported case. If such a claim is deemed necessary, authors should explain their reasoning in the cover letter and provide a detailed Appendix describing how they came to this conclusion. Describe search strategies, search terms, databases queried, and how far back these were checked. Also list textbooks and monographs that were searched to substantiate the claim. Similarly, the phrase "safe and effective" should be reserved for FDA-approved product labeling based on registered phase III trials. In other settings, the term should be avoided entirely. Acceptable terminology for a case series would include the sentence "Our patients demonstrated positive responses and the treatment was well tolerated."

Trade names
Trade names and brand names of drugs and devices may not be used in the title of the paper. They may appear only once in the paper and should be placed in parentheses along with their manufacturer and the manufacturer's location following the first mention of the generic name in the text. Thereafter, only generic names should be used throughout the article.

Sections/article type guidelines
Manuscripts should be concise and to the point. Inclusion of textbook-type material is strongly discouraged, as is repetition of the same statements in the Introduction and Discussion. The Introduction and Discussion should pertain directly to the study being reported, and not contain a lengthy review of a disease entity or its treatment.

Case Reports
Concise descriptions detailing one or two patients and early reports of new drug reactions will be considered for the journal. Cases for consideration should fall into one of the 4 following categories. 1) The unique, or nearly unique, case that appears to represent a previously undescribed syndrome or disease. 2) The case with an unexpected association of two or more diseases or disorders that may represent a previously unsuspected causal relation. 3) The case representing a new and clinically important variation from an expected pattern. 4) The case with an unexpected evolution that suggests a possible therapeutic or an important adverse drug effect. Case reports should be subdivided into sections, eg, Introduction, Case report, Discussion, bibliography.
Repetition of introductory, textbook type information should be avoided. Manuscripts should center on the case at hand, and should not take the form of a lengthy "Case and Review." All patient information in Case Reports must be adequately de-identified. If identifying information or figures are included, express written permission from the patient(s) must be provided at the time of manuscript submission. Case Reports must not exceed 1000 words and should not cite more than ten references. Up to four figures or tables may be included. Each part of a multi-part figure is counted toward the maximum allotment, eg, a figure 1A and 1B are considered 2 figures. Case Reports are designated for online-only publication.

Letters to the Editor

Letters commenting on material previously published in the JAAD Case Reports will be considered for the Letters to the Editor section.

Letters to the Editor responding to articles that have appeared in the JAAD Case Reports will be sent for response to the authors of the article being commented upon. This response may be published or sent directly to the commentator at the discretion of the editor. Questions or comments that could be addressed directly to authors (including complaints about missed citations) should be sent directly to the author, rather than involving the JAAD Case Reports as an intermediary.

Article structure

Title page

On the title page, include the title, authors' full names, highest earned academic degrees, and institutional affiliations and locations. Include a separate word count for the text (excluding references, figures, and tables). Please also include a reference count, figure count, and table count. The title page must also include a statement of all funding sources for the work as well as a publishable conflict of interest statement (see the Conflict of Interest Section above for details). Designate one author as correspondent (provide address, telephone and fax numbers, and e-mail address) to receive communications from the Editorial Office and galley proofs from the publisher. The name and address of the author who will receive reprint requests should be noted if different from the correspondent. The corresponding author should promptly inform the Editorial Assistant (JAADCR@aad.org) of any change in e-mail or mailing address.

Key words

A list of 3-5 key words (eg, Key words: sunscreen; UVA protection; UVB protection) should appear on the title page.

Classifications

Select at least 3 classifications to facilitate matching the manuscript with reviewers. You can do this in EES by clicking 'Select Document Classifications' to open a window containing a list of the classifications pertaining to the Journal. Then click the check-box next to any classification you wish to select. Click 'Submit' when you are done.

Abbreviations and acronyms

Only standard abbreviations are to be used. Consult Scientific Style and Format by the Council of Biology Editors or the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable and they should be avoided in the abstract whenever possible. A laboratory or chemical term or a disease process must be spelled out at first mention, with the acronym or abbreviation following in parentheses. List all abbreviations and acronyms on a separate page within the manuscript document before the references.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Artwork

For specific information about how to format your artwork, please visit http://www.elsevier.com/artworkinstructions.

Image manipulation

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they
do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

Black and white graphs must be legible and clearly printed. The fill for bar graphs or pie charts should be distinctive; avoid shading or dotted patterns. Use thick, solid lines and bold, solid type. Place lettering on a white background; avoid reverse type (white lettering on a dark background). All lettering must be done professionally and should be in proportion to the drawing, graph, or photograph. Typewritten or freehand lettering is unacceptable. Consistency in size within the article is strongly preferred. Any special instructions regarding sizing should be clearly noted.

For color photographs, if prints have been enhanced, a preference for reproduction should be noted. The quality of the reproduction depends entirely on the quality of the illustrations submitted. Please note that 35 mm transparencies are normally enlarged to twice their original size. If it is important to deviate from this standard, please indicate when file material is submitted. Top for each print (and transparency) must be noted.

Figures and tables
Tables, figures, and legends should supplement, not duplicate, the text. Clinical photographs should be of high quality without distracting backgrounds. Please visit our website (http://www.jaadcasereports.org) for examples of acceptable and unacceptable illustrations. A reasonable number of halftone photographs and line drawings will be published at no extra charge to the author. Color illustrations will be reviewed by the Editor and those considered appropriate will be published free of charge to the authors. Figures must be cited in the text and numbered in order of mention. Figures must have an arrow marking the top edge and they must be numbered consecutively (ie, 1, 2, 3). Multi-part figures must be marked clearly (ie, 1A, 1B, 1C). Legends should start with the name of the disease or condition being depicted. For graphics files, use Adobe Photoshop and save the files in either TIF or EPS format. DO NOT SUBMIT figures in Word, PowerPoint, or Excel formats. If they have not already done so, authors will be contacted to provide print-quality figures after their articles have been accepted.

Figure format
Figures may be submitted in electronic format. All images should be at least 5 inches wide. Images should be provided in TIF, EPS, or JPEG format. Graphics software such as Photoshop and Illustrator, not presentation software such as Microsoft Word, PowerPoint, CorelDraw, or Harvard Graphics, should be used in the creation of the art. Color images must be CMYK and at least 300 DPI. Gray scale images should be at least 300 DPI. Combinations of gray scale and line art should be at least 1200 DPI. Line art (black and white or color) should be at least 1200 DPI.

Illustration services
Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure legends
If you include any figures with your submission, you must also include a figure legend. Figure legends should start with the name of the condition or disease being depicted. Legends should be typed double-spaced and inserted after the references within the manuscript document. If an illustration has been published previously, full credit to the original source must be given in the legend and permission to reprint must have been obtained from the copyright holder. For histologic/microscopic figures, the legend must specify stain. Arrows and arrowheads should be used freely to clarify findings. Please note that online-only figures also require legends.

Tables
Tables should be self-explanatory and numbered sequentially in Roman numerals in order of their mention in the text. Tables should be submitted in Word, WordPerfect, RTF, or Text formats; Word and WordPerfect are preferred. A brief title should be provided for each. If a table, or any data therein, has been published previously, full credit to the original source must be given in a footnote.

Permissions and patient consent forms
Direct quotations, tables, or illustrations that have appeared in copyrighted material must be accompanied upon submission by written permission for their use from the copyright owner and the original author along with complete information as to their source.
Patient consent forms for publication of recognizable photographs must be sent to the Editorial Office upon submission of the article. Patients must be identified by numbers and/or letters, not by name, initials, or hospital record number. Institutional consent must also be available.

Patient consent must accompany recognizable photographs of patients at the time of submission. Photographs and text (such as details in the case report or genetic pedigree) must be deidentified to protect patient confidentiality unless patient consent has been documented. In the event that patient consent has not been documented, please crop the photo and/or obstruct the eye region in such a manner that the patient cannot be recognized. The altered figure must be unidentifiable unless documentation of patient consent is provided.

Personal communications should not be cited in the reference list but may appear parenthetically in the text. References must be identified in the text by superscript Arabic numerals in order of their mention. References should not be formatted as footnotes, but should appear in a list at the end of the text. The reference list should be typed double-spaced and in numeric sequence. The format should conform to that set forth by the International Committee of Medical Journal Editors and the National Library of Medicine (http://www.nlm.nih.gov/bsd/uniform_requirements.html). Journal titles should conform to the abbreviations in Cumulated Index Medicus.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

Reference style
List the first six authors followed by et al.:


Journal abbreviations source
Journal names should be abbreviated according to the List of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php.

Procedure for review
The JAAD Case Reports employs a confidential and anonymous peer review process to evaluate submitted papers for possible publication. A small number of papers are rejected after in-house editorial review when editors deem that the paper is not appropriate for the Journal or is not of sufficient quality to warrant further evaluation.

The author may suggest several reviewers for the manuscript. We will attempt to use at least one suggested reviewer. The editorial staff will review the manuscript and will ordinarily send it to at least two reviewers. Reviewers will pay particular attention to scientific accuracy, relevance, novelty, importance, appropriate style, and quality of illustrations.

First decisions (accept, revise, reject) are usually made within 3 to 5 weeks; longer delays are possible. Some
degree of manuscript revision should be expected and regarded as constructive. A request to submit a revised
manuscript does not guarantee that it will be accepted, only that it will be reconsidered, perhaps after additional
peer review. The final editorial decision rests not only on the validity of the report and the opinions of the
reviewers, but also on the editors' judgment of a paper's novelty, clarity, importance, and likely degree of
interest to the readership.

After Acceptance

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a
unique alpha-numeric character string which is assigned to a document by the publisher upon the initial
electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document,
particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of
a correctly given DOI (in URL format; here an article in the journal Physics Letters B):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-
mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can
download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this
you will need to download Adobe Reader version 7 (or higher) available free from http://get.adobe.com/reader.
Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the
Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for
any reason, this is not possible, then mark the corrections and any other comments (including replies to the
Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use
this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this stage with
permission from the Editor. We will do everything possible to get your article published quickly and accurately --
please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back
to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections
cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the
publication of your article if no response is received.

Electronic publishing

Articles for the JAAD Case Reports will publish online-only. Please note that online publication is considered a
bonafide form of publication and can be cited using the DOI number located in the footnotes on the first page of
each article.

Author Inquiries

For inquiries relating to the submission of articles (including electronic submission) please visit this journal's
homepage. For detailed instructions on the preparation of electronic artwork, please visit
http://www.elsevier.com/artworkinstructions. Contact details for questions arising after acceptance of an article,
especially those relating to proofs, will be provided by the publisher. You can track accepted articles at
http://www.elsevier.com/trackarticle. You can also check our Author FAQs at